TOP TEN perturbations for 38990_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38990_at
Selected probe(set): 212987_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38990_at (212987_at) across 6674 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):3.753213
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):3.339634
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

omeprazole study 6 (600uM) / vehicle (DMSO) treated hepatocyte sample

Relative Expression (log2-ratio):-3.1834145
Number of Samples:2 / 2
Experimental omeprazole study 6 (600uM)
Hepatocytes treated with compound: omeprazole (600uM; CHEMBL1503) for 24 hours. ATC code:
Control vehicle (DMSO) treated hepatocyte sample
Hepatocytes treated with vehicle (DMSO) for 24 hours.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.9756851
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

sulindac study 5 (3000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-2.9248972
Number of Samples:2 / 2
Experimental sulindac study 5 (3000uM)
Hepatocytes treated with compound: sulindac (3000uM; CHEMBL15770) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.602581
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.5662355
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

sickle cell disease study 2 (Pax) / normal blood sample

Relative Expression (log2-ratio):2.5048409
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Pax)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion step.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step.

sickle cell disease study 2 (Globin red.) / normal blood sample

Relative Expression (log2-ratio):2.3656483
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Globin red.)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclear™-Human kit.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit including an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclearTM-Human kit.

omeprazole study 5 (600uM) / vehicle (DMSO) treated hepatocyte sample

Relative Expression (log2-ratio):-2.3504477
Number of Samples:2 / 2
Experimental omeprazole study 5 (600uM)
Hepatocytes treated with compound: omeprazole (600uM; CHEMBL1503) for 8 hours. ATC code:
Control vehicle (DMSO) treated hepatocyte sample
Hepatocytes treated with vehicle (DMSO) for 8 hours.